Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 51, 2084-2091, April 15, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fokas, A. S.
Right arrow Articles by Clarkson, B. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fokas, A. S.
Right arrow Articles by Clarkson, B. D.

Mathematical Model of Granulocytopoiesis and Chronic Myelogenous Leukemia1

A. S. Fokas2, J. B. Keller and B. D. Clarkson

Department of Mathematics and Computer Science and Institute of Nonlinear Studies, Clarkson University, Potsdam, New York 13699-5815 [A. S. F.]; Department of Mathematics, Stanford University, Stanford, California 94305 [J. B. K.]; and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 [B. D. C.]

We present a mathematical model of granulocytopoiesis that depends on certain physiologically meaningful parameters. By choosing different values of these parameters, the model describes both the normal process and that in chronic myelogenous leukemia (CML). The model fits all the available experimental data tested. Furthermore, it shows how the CML cells can ultimately outnumber the normal cells and how this process can be very slow. The model provides a quantitative approach to the relationship between proliferation and maturation and resolves the apparent contradiction between decreased proliferation and increased production, by assuming that a greater fraction of CML cells is produced by division rather than by maturation. The model should be helpful in designing experiments to better define the abnormalities of proliferation and maturation in CML and in seeking to define the specific alterations in the cell regulatory networks resulting from the production of the chimeric p210bcr-abl protein characteristic of CML.

1 A. S. F. and J. B. K. were partially supported by the Office of Naval Research, the National Science Foundation, and the Air Force Office of Scientific Research. B. D. C. was partially supported by the Rudin Foundation, the United Leukemia Fund, and Grant CA20194 from the NIH.

2 To whom requests for reprints should be addressed.

Received 10/29/90. Accepted 2/ 5/91.




This article has been cited by other articles:


Home page
BloodHome page
C. Haurie, D. C. Dale, and M. C. Mackey
Cyclical Neutropenia and Other Periodic Hematological Disorders: A Review of Mechanisms and Mathematical Models
Blood, October 15, 1998; 92(8): 2629 - 2640.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A.L. Petzer, C.J. Eaves, M.J. Barnett, and A.C. Eaves
Selective Expansion of Primitive Normal Hematopoietic Cells in Cytokine-Supplemented Cultures of Purified Cells From Patients With Chronic Myeloid Leukemia
Blood, July 1, 1997; 90(1): 64 - 69.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1991 by the American Association for Cancer Research.